Literature DB >> 27885968

Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.

Anna Mosikian1, Antonina Dolgorukova1, Alsu Zalevskaya1.   

Abstract

AIM: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. MATERIALS &
METHODS: We have collected the current data on correlation between SUs pharmacodynamics and CYP2C9 polymorphisms. We have evaluated the frequency of CYP2C9 polymorphisms in Russia by reviewing the literature published from 2004 to 2015 on Russian CYP2C9.
RESULTS: The genotype *1/*1, which confers risk for treatment failure, has a higher frequency (81.92%) in the non-Caucasians than that (64.92%) in the Caucasians. The Caucasians have a frequency (3.58%) of the poor metabolizers (*2/*2, *2/*3 and *3/*3) eight-times higher than that (0.44%) in the non-Caucasians, predisposing an increased risk of hypoglycemia.
CONCLUSION: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians.

Entities:  

Keywords:  CYP2C9; sulfonylureas; worldwide Russians

Mesh:

Substances:

Year:  2016        PMID: 27885968     DOI: 10.2217/pgs-2016-0121

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  2 in total

Review 1.  Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.

Authors:  Yana Anfinogenova; Elena V Grakova; Maria Shvedova; Kristina V Kopieva; Alexander T Teplyakov; Sergey V Popov
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

2.  The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.

Authors:  Meisam Saberi; Zahra Ramazani; Homeira Rashidi; Alihossein Saberi
Journal:  Vasc Health Risk Manag       Date:  2020-06-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.